Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label post-marketing study of 2-dose versus 3-dose Cervarix schedules in Chinese females
CTR20242107Phase 4Terminated
- Sponsor
- GSK
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ (AIS), sponsored by GSK. Started Jun 2024; status: terminated.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)adenocarcinoma in situ (AIS)
Beyond the preview
Go deeper on CTR20242107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242107.